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The field of cancer research has grown immensely in recent decades and has led to a better
understanding of the causes of the disease, as well as greatly improved treatment for various
types of cancers, especially breast cancer. One of the most effective treatments involves the
chemotherapeutic drug doxorubicin (DOX). DOX is an effective tool against all types of breast
cancer, especially against triple negative breast cancer. However, DOX causes adverse side
effects that include damage to the heart and skeletal muscle, particularly above specific
cumulative doses. Recent evidence suggests that embryonic stem cell-derived (ES) exosomes,
nanoscale extracellular vesicles that carry proteins, messenger RNA, and microRNAs, may be
able to mitigate some of the cardio- and cytotoxic effects of DOX without reducing its efficacy.
The present study examined the effects of combined treatment with DOX (1 μM) and ES
exosomes (10 μg/mL) on three cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-468. The
DOX/ES exosomes treatment increased cell death and increased apoptosis specifically compared
to control, as measured via dye exclusion assay and flow cytometry. The treatment also
decreased cell growth compared to control, as measured via MTS cell proliferation assay. In
addition, DOX/ES exosomes treatment also increased expression of pro-apoptotic Bax while
decreasing the expression of anti-apoptotic Bcl-2, as measured via Western blot. Finally, the
DOX/ES exosomes treatment decreased expression of miR-200c, a microRNA associated with
preventing epithelial-mesenchymal transition, a process that is integral to metastasis.
Although increased cell death and apoptosis and decreased cell proliferation implies that
the DOX/exosomes treatment is effective against cancer, the decrease in miR-200c expression
may suggest the opposite and will be investigated further in future studies. Even so, the results of
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this study suggest that exosomes may be an important component to reduce the harmful effects
of cancer treatment in the future.
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All living things exist as a constant balance of growth and death. During adulthood,
healthy humans enjoy an even balance between cell proliferation and cell death, but during
certain stages of life, and during certain disease states, proliferation can greatly outpace death. In
the developing embryo, cell division occurs at a rapid pace to meet the needs of the growing
organism. At the same time, certain highly specific populations of cells die off to allow organs to
take certain shapes or to promote the formation of channels and orifices. For example, the fetal
heart develops as two separate endocardial tubes. As the surrounding cells grow or die off, these
tubes are pushed closer and closer together until they fuse, a feat accomplished by the death of
cells in the tubes’ walls (van den Hoff et al., 2000). Cardiac development continues to rely on
strategic growth and death as the now-fused vessel twists and segments, eventually forming the
mature four-chambered heart.
The same processes that allow for rapid fetal growth, however, can also lead to harmful
or even fatal consequences. Cancer is one such outcome. Essentially, cancerous growth occurs
when a population of cells loses its growth inhibitions and multiplies out of control. Cells that
would normally divide slowly now replicate at a rapid clip, and the processes that would
normally cause cells in such a frenzy to commit suicide rather than endanger the larger organism
fail to activate. As they divide, these aberrant cells continue to accumulate genetic damage,
allowing them to change shape, leave their anchor points, and establish new colonies elsewhere
in the body, a process called metastasis.
This paper will begin with background information on cancer, including the process of
cancer transformation and characteristics important to all cancers. I will then discuss breast
cancer specifically, as well as strategies to combat its growth and spread. Next, I will elaborate
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on the process of cell death, the intended consequence of cancer treatment, and its various forms

and I will consider the risks of administering treatment that causes it. I will review the properties
of exosomes, acellular vesicles released by many cell types, and their implications on cancer
treatment. Finally, I will discuss the current study, its results, and the conclusions drawn from
those results.
1.1. Challenges of Cancer Research
Studying cancer cells is challenging for a variety of reasons, not least because they defy
easy classification. First, it was assumed that primary tumors—that is, tumors present within an
organism from which a cancer cell line may be isolated—begin from a singular cell or group of
clonal cells and then grow to form a larger mass. Although some tumors likely are the result of a
single (or group of clonal) mutated cells, evidence suggests that many are not (Parsons, 2008).
Instead, tumors can form as a result of disrupted cell signaling processes caused by, for example,
inflammation and its resulting destruction to the extracellular matrix (ECM) and invasion of
immune cells. Epithelial cells attached to the ECM may then sustain genomic damage that then
spirals into tumor formation. Alternatively, inflammatory processes may provoke cells with
existing precancerous abnormalities, either genetic or epigenetic, into cancerous proliferation
(Bissell & Radisky, 2001). Such circumstances suggest the possibility that distinct, neighboring
cells may be affected en masse by a single precipitating event, which would cause them to
incorporate into a single, polyclonal tumor.
By itself, many tumors’ polyclonal origins make propagating a cell line from individual,
“representative” cells quite difficult. However, even monoclonal tumors are quite heterogenous
(Loeb, Loeb, & Anderson, 2003). A tumor can have similar or even greater complexity to a
normal organ: many different cell types comprise a single tumor, including cancer cells, cancer-
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associated fibroblasts (CAFs), cancer stem cells (CSCs), immune inflammatory cells, endothelial
cells (that form the tumor vasculature), and associated pericytes (Hanahan & Weinberg, 2011).
All six of these cell types work together to sustain the tumor as a whole and thus none are totally
representative of the tumor in isolation. What is more, many cancer cell lines used in research
were not originally derived from a solid tumor but were isolated from metastases present in
ascites fluid or pleural effusion (in the case of the MCF7 line, for example) (Lacroix & Leclercq,
2004). These cells have already undergone various changes to facilitate metastasis, including the
process of epithelial-mesenchymal transition (EMT), and therefore may be yet another step
removed from the tumor in which they originated (Birchmeier & Behrens, 1994).
1.2. Genetic Foundations of Cancer
Despite the difficulties inherent in studying cancer, many of its properties have been
elucidated over the past few decades. Before a deeper discussion of the characteristics that
underly the formation and growth of tumors, it is important to discuss the concept of oncogenes
and tumor suppressor genes and their involvement in tumor formation.
Certain genes—proto-oncogenes and tumor suppressor genes—have a special
relationship with cancer growth and development. Mutations in both types of genes can lead to
the induction of cancer, though in opposite ways. First, genes that can be classified as “protooncogenes” are involved in pathways that control cell growth. In their normal state, they ensure

that cells that divide to replenish cells lost through normal means—especially epithelial cells like
those in the skin or gut lining—will continue to do so. However, if a cell develops a mutation to
a proto-oncogene that circumvents the normal safeguards that keep cell growth in check, the
proto-oncogene becomes an oncogene and the cell may begin to divide too rapidly. As the
growing population of oncogene-containing cells accumulates further mutations, the cells can
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form a tumor. Because the formation of an oncogene represents a gain-of-function mutation,
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only one copy need be damaged to promote cell proliferation.
On the opposite side of the coin, tumor suppressor genes code for proteins that limit cell
growth. These genes keep actively dividing cells from dividing too fast by acting as checks on
the cell cycle, growth signaling, or genetic integrity. They also function in mature cells to
maintain their differentiated state. If a tumor suppressor gene is damaged, the cell may begin to
grow out of control or rapidly accumulate genetic damage. Both circumstances promote the
formation of a tumor. However, because a mutated tumor suppressor gene represents a loss-offunction mutation, both copies of a given gene must be mutated to achieve the maximum
carcinogenic power. Of course, because tumor suppressor genes and proto-oncogenes both help
to prevent cancer when functioning normally, damage to both types of genes greatly increases
the likelihood of a malignancy (Lodish et al., 2000).
1.3. Cancer’s Defining Characteristics
The genetic changes that give rise to cancer describe discrete events, but cancer itself is
more than the sum of its genetic parts. Luckily, the past decades have given us a solid framework
upon which to build an understanding of the myriad mechanisms underlying cancer genetics and
signaling. Hanahan and Weinberg (2000) described seven hallmarks of cancer that are necessary
for its formation and proliferation. Later, the researchers added two more hallmarks based on
research accomplished in the intervening years (Hanahan & Weinberg, 2011). I will describe
each hallmark briefly.
1.3.1. Growth signal self-sufficiency. First, cancer must be self-sufficient in growth
signals. Normal human cell growth is regulated by many different growth signals that govern
whether and how quickly cells will divide and how less-differentiated cells will change to
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able to manufacture signals that stimulate their own growth (Sporn & Todaro, 1980). In other
cases, the receptors that would bind growth factors are overexpressed, allowing more receptors
to be activated by the same signal. In addition, increased interaction between receptors ultimately
results in increased growth factor sensitivity (Slamon et al., 1987; Yarden & Ullrich, 1988).
Finally, a genetic mutation can alter the structure of a receptor in a way that allows it to fire
constitutively, even in the absence of the growth factor stimulus (Bishayee, 2000).
1.3.2. Resistance to anti-growth signals. To succeed, cancer cells must not only
establish their independence from growth signals but also develop resistance to anti-growth
signals. Often, this means developing a means to bypass cell cycle checks that would normally
cause maturing cells to arrest in the G0 or G1 phases. The main regulators of progression from G1
into S phase are the retinoblastoma protein (pRb) and the related proteins p107 and p130. The
transcription factor E2F is responsible for controlling expression of many genes necessary to
advance through the cell cycle; pRb sequesters E2F, halting the cell cycle, but phosphorylation
of pRb releases E2F, allowing the cell to proceed through the cell cycle. Transforming growth
factor β (TGFβ), a cytoplasmic signaling molecule, blocks pRb phosphorylation, preventing the
cell from leaving G1 and therefore halting proliferation (Weinberg, 1995). TGFβ is therefore an
anti-growth signal. If TGFβ activity is disrupted—for example through mutations to TGFβ
receptors (Markowitz et al., 1995), mutation (Schutte et al., 1996) or deletion (Chin, Pomerantz,
& DePinho, 1998) of its downstream targets, or deletion of pRb itself or sequestration by viral
oncoproteins (Dyson, Howley, Münger, & Harlow, 1989)—the cell can bypass the G1 checkpoint
and continue to proliferate.
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growth signals and ignore anti-growth signals, they must also be able to avoid death signals. In
normal cells, removal of an important growth factor—e.g. testosterone for prostate gland cells—
or addition of certain stimuli—e.g. glucocorticoid hormones for immature thymocytes—can
cause apoptosis, a form of programmed cell death (Alison & Sarraf, 1992), as can a variety of
other more specific stimuli. The process of apoptosis itself is discussed in greater detail below,
but to give a brief description, a cell that has received an apoptotic signal begins to shrink as the
cell’s components are degraded into fragments. The fragments are packaged into membranebound compartments that break apart from one another in a process called blebbing. The vesiclelike apoptotic bodies are then subsumed by phagocytic cells and degraded (Kerr, Wyllie, &
Currie, 1972).
Cell death in tumors is a major determinant of the tumor’s growth rate (Alison & Sarraf,
1992). As such, the capacity to avoid apoptosis is essential for a tumor to continue to grow.
Cancer cells can avoid apoptosis (and other forms of cell death) by several means. A tumor
suppressor gene, TP53, the gene that encodes the protein p53, is mutated across various forms of
cancer. In fact, roughly half of all tumors diagnosed each year contain TP53 mutations (Harris,
1996; Levine, 1997). The protein p53 is an important signaling intermediary to several pathways,
most notably apoptosis. As mentioned above, apoptosis can be caused by various stimuli.
However, many of the signaling pathways involved funnel through p53, meaning that the loss of
p53 or expression of an aberrant protein abrogates the apoptotic effect of several different
signals, including hypoxia, oncogene overexpression, and DNA double-strand breaks (Levine,
1997). As a result, cells with defective or missing p53 are susceptible to further perturbation of
signaling pathways and are less likely to undergo “altruistic suicide” via apoptosis.
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independence, resistance to anti-growth signals, and resistance to apoptosis—lay the groundwork
for unrestrained proliferation, there are still more safeguards that prevent unlimited growth.
Normal cells in culture—and likely in vivo as well—will only go through a finite number of
replications before they lose their replicative ability, a state termed “senescence” (Hayflick,
1997). This phenomenon is attributed to the progressive shortening of telomeres, repeating
regions at the end of the chromosome that seem to protect from excessive recombination or even
end-to-end fusion of one chromosome to the next. During normal DNA synthesis, telomeres lose
approximately 65 bp per replication (Counter et al., 1992). However, disabling certain tumor
suppressor genes—for example, RB (the gene encoding the pRb protein) and TP53 in cultured
human fibroblasts—allows cultured cells to continue replicating past the point at which they
would ordinarily enter senescence. If allowed to continue replicating, the altered cells will
eventually reach a crisis point at which a massive number of cells will die off, leaving behind
only a small number of survivors (1 in 107). The cells that remain are immortal, able to replicate
indefinitely (Wright, Pereira-Smith, & Shay, 1989).
On a molecular level, cancer cells employ one of two strategies to continue replicating
past the normal senescence cutoff. The vast majority upregulate telomerase, a reverse
transcriptase that adds hexameric repeats to the ends of the telomeres, which allows cells to
replicate with no net loss of telomeric DNA (Bryan & Cech, 1999; Counter et al., 1992). Other
surviving cells do not express telomerase but instead maintain their telomeres through
homologous recombination (Bryan, Englezou, Gupta, Bacchetti, & Reddel, 1995; Cesare &
Reddel, 2010; De Vitis, Berardinelli, & Sgura, 2018). Regardless of the method, maintaining
telomere length seems to be required for cellular immortalization.
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and nutrients and must be able to dispose of waste to survive (albeit at different rates than normal
cells). Therefore, tumors must be able to recruit blood vessels to grow past a microscopic size. In
normal adult tissue, vascular growth—angiogenesis—is only active during processes like wound
healing or menstrual cycling (Bouck, Stellmach, & Hsu, 1996). Pre-malignant cells initially lack
the ability to attract new blood vessels. As they transform into malignant tumors, they quickly
develop the capacity to induce angiogenesis (D. Hanahan & Folkman, 1996).
Angiogenesis is governed by multiple factors, both pro- and anti-angiogenic.
Thrombospondin-1 (TSP-1) was the first discovered and is perhaps the best known antiangiogenic factor (Good et al., 1990). Many other anti-angiogenic factors are derived from larger
proteins with functions unrelated to angiogenesis and include angiostatin and other “statins”
derived from collagens. On the other hand, pro-angiogenesis factors tend to be receptor tyrosine
kinase ligands and include vascular endothelial growth factor (VEGF), fibroblast growth factors
(FGFs), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF) (Bergers &
Benjamin, 2003). In normal cells, stimuli such as the hypoxic environment that develops around
a wound can induce angiogenesis to promote wound healing, but once the wound has closed and
the oxygen supply has returned to the healing tissues, angiogenesis ceases (Knighton, Silver, &
Hunt, 1981). As a cell transforms, mutation or loss of certain tumor suppressor genes or
induction of oncogenes can begin to tilt the balance of signals toward pro-angiogenesis. Also, as
a tumor grows larger, the physical mass and size begin to restrict oxygen delivery and waste
removal by native blood vessels, stimulating pro-angiogenic processes. This tilt towards proangiogenic signaling is often referred to as the “angiogenic switch” that allows cancer cells to
continue to proliferate (Dor, Porat, & Keshet, 2001). In some cases, the angiogenic switch can be

ES EXOSOMES INCREASE DOX ACTIVITY IN BREAST CANCER

flipped indirectly when a protein regulating an angiogenesis regulator is overexpressed or

9

downregulated itself. For example, p53, a master tumor suppressor gene discussed above with
respect to apoptosis, also acts as a transcription factor to positively regulate TSP-1 synthesis. If
p53 is lost due to mutation or another means, expression of TSP-1 will decrease. Because TSP-1
inhibits angiogenesis, the loss of this protein allows the balance to tip toward pro-angiogenesis
and furthers tumor growth (Dameron, Volpert, Tainsky, & Bouck, 1994).
1.3.6. Metastasis. Tumor growth by itself presents a challenge to the system that the
tumor has colonized. Any tumor will use up extra energy and encroach on nearby tissues, and
many tumors produce the same signaling proteins as their tissues of origin, potentially interfering
with hormonal balances or other signaling systems. However, tumors that remain encapsulated
and are not near a major vessel or structure that might be compressed and damaged are generally
benign and can be treated and cured (Talmadge & Fidler, 2010). To become malignant, tumors
must be able to metastasize. That is, cells must leave their site of origin, travel through the body
(usually through the vasculature or lymphatic system), and establish a new colony elsewhere.
Unlike many of the hallmarks discussed above, metastasis most often occurs later in tumor
development: the likelihood of metastasis tends to corelate with tumor size, meaning that smaller
tumors generally (but not always) have not metastasized by the time they are detected, while
larger tumors are often already metastatic (Talmadge & Fidler, 2010).
Metastasis tends to proceed through a series of discrete steps. Once a tumor has
established itself and undergone vascularization, cells near blood or lymphatic vessels must
penetrate the basement membrane surrounding the tumor and then that surrounding the vessel in
question. The migrating cells then pass through the vessel wall in a process known as
transendothelial migration or intravasation and travel through the bloodstream or lymphatics,
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Condeelis, 2017; Nieto, Huang, Jackson, & Thiery, 2016). Metastatic cells of a given origin will
tend to colonize specific tissues, according to the “seed and soil” hypothesis first proposed in
1889 (Paget) and born out in more recent years (Fidler, 2003). In fact, it has become increasingly
clear that metastatic tumors induce a “pre-metastatic niche” through system-wide release of
tumor-secreted factors and extracellular vesicles. The pre-metastatic niche exists as a preset
environment awaiting the arrival of a CTC (Peinado et al., 2017). Therefore, once a CTC reaches
a tissue containing such a niche, it can leave the vessel within which it traveled through a process
called extravasation and travel to the site of colonization. To reach what will become the
metastatic niche, the CTC must break through the extracellular matrix (ECM) surrounding the
organ to be colonized. To do this, cancer cells employ protrusions called invadopodia that attach
to and degrade the ECM (Liotta, 1986; Murphy & Courtneidge, 2011). At this point, the cell has
bypassed the body’s safeguards against metastasis and can begin to establish a new tumor distant
from its site of origin.
1.3.6.1. Epithelial-mesenchymal transition. Aside from the various adaptations cancer
cells need to develop to be able to successfully travel from the tumor site to the metastatic niche,
metastatic cells also need to undergo a transformation from attached, cuboidal or squamous
epithelial-like cells to dedifferentiated, front-back polar mesenchymal-like cells (Nieto et al.,
2016). The process governing this transformation is referred to as epithelial-mesenchymal
transition (EMT). At the other end of the journey, the reverse process, mesenchymal-epithelial
transition (MET) primes the metastatic cell for cell-cell attachment and other necessities for
tumor formation. EMT relies on a variety of stimuli, including protein transcription factors
(referred to as EMT-TFs), microRNAs, and epigenetic and post-transcriptional regulators.
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Though a multitude of factors control the EMT process, the most commonly recognized markers
of epithelial-like cells are E-cadherin, occludins, and cytokeratins, while the canonical markers
of mesenchymal-like cells are N-cadherin and vimentin (Thiery, Acloque, Huang, & Nieto,
2009).
1.3.7. Metabolic modifications. In addition to the longer-established characteristics of
cancers described above, more recent research has brought additional characteristics to light.

Like many aspects of cancer development, tumor metabolism is quite unlike that of normal cells.
Instead of utilizing the citric acid cycle and oxidative phosphorylation in the presence of oxygen
to generate ATP from glucose and other glycolytic molecules, many forms of cancer
preferentially employ lactic acid fermentation. Although the anomalous nature of cancer cell
metabolism was observed as long ago as 1927 (Warburg, Wind, & Negelein), it was not clear for
many years why cancer cell metabolism should differ so drastically from that of normal cells.
Especially when one considers the rapid rate of growth of malignant tumors, it would seem
counter-productive to employ a form of energy conversion that is grossly inefficient at producing
ATP compared to the alternative. Recent interest in cancer metabolism from a therapeutic
perspective has driven new inquiry into Warburg’s original observation. In particular, there has
been renewed attention to the hypothesis that cancer cells employ lactic acid fermentation in
order to preserve carbon skeletons for use in macromolecule synthesis (nucleotides, amino acids,
lipids, etc.) (Vander Heiden, Cantley, & Thompson, 2009). Stranger still, tumors have been
documented that contain two populations of cells that use opposite metabolic strategies. In these
tumors, one population of cells, deprived of oxygen by their distance from the blood supply,
employs glycolysis as described above and releases built-up lactate. The other, by virtue of its
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phosphorylation (Feron, 2009; Semenza, 2008).
Interestingly, the human placenta utilizes a similar metabolic strategy to cancer’s
“aerobic glycolysis.” However, instead of regenerating NAD+ by converting glucose to lactic
acid, NAD+ is regenerated via the polyol pathways (Burton, Jauniaux, & Murray, 2017),
bolstering the idea that cancer does not create novel pathways but instead subverts extant
strategies for its own purposes.
1.3.8. Immune system evasion. Finally, cancer cells’ ability to evade the immune
system has been highlighted recently as a possible line of attack to combat the growth of tumors.
Much energy has gone into the idea that the immune system itself can be tuned to recognize
cancer cells by the strategies they use to avoid detection (Yousefi, Yuan, Keshavarz-Fathi,
Murphy, & Rezaei, 2017). Indeed, the ability to avoid immune detection and response seems to
be a critical determinant of which cancer cells survive and proliferate and which are killed off
before they can take root.
The concept of immune surveillance, the idea that the immune system monitors
neoplastic activity and kills off the vast majority of cancerous cells before they can form tumors,
has existed since at least 1909 (Ehrlich). However, evidence for the hypothesis was not available
until the 1950s, and the ensuing years saw the growth of research that seemed to discredit
immune surveillance entirely (Dunn, Bruce, Ikeda, Old, & Schreiber, 2002; Ribatti, 2017).
Nevertheless, in the past two decades new research has started to back up immune surveillance.
Experiments on mice lacking critical components of the immune system have shown an increase
in cancers not caused by viral infection in these mice, and observational experiments of
immunocompromised humans have shown similar results (Dunn et al., 2002). Furthermore,
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mice and vice versa have shown that tumors grown in animals lacking an immune system are
more immunogenic than those from immunocompetent individuals. These results suggest that
many of the tumors that form in the absence of an immune system would have been weeded out
in healthy individuals (Shankaran et al., 2001). Although there are still many questions
surrounding the role of the immune system in fighting cancer, researchers have generally
accepted the idea that cancer must evade the immune system as a prerequisite for successful
growth (D. Hanahan & Weinberg, 2011).
1.4. Breast Cancer: Description and Treatment
Now that I have laid out the defining characteristics of cancer as they are currently
understood, I will shift my focus to breast cancer specifically. Breast cancer has been recognized
as a distinct disease since antiquity; descriptions date as far back as the ancient Egyptians circa
1600 BCE (Breasted, 1930). Today, breast cancer can be divided into three subtypes based on
expression of three cell-surface receptors: the estrogen receptor (ER), the progesterone receptor
(PGR), 1 and a third receptor known as HER2 (human epidermal growth factor receptor 2) or
erbB2. 2 The first subtype, defined by tumors that express ER and PGR and do not overexpress
HER2, is also the most treatable and includes approximately 70% of patients. The second
subtype consists of tumors that overexpress HER2 (15-20% of patients), and the third consists of
tumors that express none of the three markers (10-15% of patients) and is commonly referred to
as “triple negative” breast cancer (TNBC). TNBC is the most dangerous subtype: it is most likely
to recur, has the worst 5-year survival rate (85% versus 94% and 99% for ER/PGR positive and

1
2

ER and PGR are collectively referred to as HR, hormone receptors.
HER2/erbB2 has no ligand-binding domain (Zurrida & Veronesi, 2015).
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years for both other subtypes) (Waks & Winer, 2019).
Tumor subtype is relevant not only to develop an accurate prognosis but also to
determine the appropriate systemic therapy for non-metastatic cancers. Patients with HR positive
tumors can be treated with hormone therapy along with chemotherapy in some cases. Patients
with HER2 positive tumors are treated with HER2-targeted antibodies or small-molecule
inhibitors combined with chemotherapy. Finally, TNBC can only be treated with chemotherapy
(barring the development of new precision-targeted treatments) (Waks & Winer, 2019).
Unlike HR positive or HER2 positive tumors, no specific therapeutic targets have been
identified for TNBC. In addition, TNBC tends to “escape” from conventional treatments and
form metastases (Khaled & Bidet, 2019; Perou et al., 2000; Sørlie et al., 2001). As such, there
has been recent interest in classifying TNBC more extensively via gene expression patterns and
epigenetics. Doing so in a clinical setting is becoming more feasible as costs decrease, but the
science is not yet well-developed (Zugazagoitia et al., 2016).
1.4.1. Treatment of breast cancer. Having described the basic characteristics unique to
breast cancer, I will now discuss the five forms of treatment currently in use. Surgery is the
oldest treatment, but surgical procedures have also changed over the years, gradually shifting
from radical excision to more conservative practices. Evidence has emerged in favor of breastconserving surgeries, especially for smaller tumors. Larger or more numerous tumors still require
mastectomy, though often without the removal of the underlying muscle. In the past, complete
axillary dissections were performed to remove possible metastases to the lymph nodes. Current
techniques allow for biopsy of only the lymph nodes with the shortest connection to the tumor
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site. More limited biopsy is associated with lower risk than axillary dissection (McDonald, Clark,
Tchou, Zhang, & Freedman, 2016).
Radiation therapy has long been used in conjunction with surgery, especially breastconserving surgery, and nowadays is often performed intraoperatively. Unfortunately, radiation
therapy can adversely affect the heart (for left-sided tumors) and the lungs (Zurrida & Veronesi,
2015).
While tumor subtype is less important for the efficacy of surgery or radiation therapy,
hormone therapy is quite effective against HR positive tumors but is ineffective against tumors
that do not express ER or PGR. Predictably, hormone therapy interacts with a tumor’s hormone
receptors, either directly in the case of tamoxifen, an ER blocker, or indirectly in the case of
aromatase inhibitors, which inhibit a key enzyme in estrogen’s biosynthetic pathway
(Rothenberger, Somasundaram, & Stabile, 2018; Waks & Winer, 2019).
Compared to hormone therapy or even surgery and radiation therapy, chemotherapy is
quite nonspecific. Chemotherapeutic agents interfere with various processes involved in cell
proliferation, killing rapidly dividing cancer cells but also normal cells such as those that make
up hair follicles or the gut epithelium, and immune cells (Zurrida & Veronesi, 2015). Although
chemotherapy is famous for its sometimes brutal adverse side effects, it is the only systemic
therapy in wide use that is effective against TNBC. Chemotherapeutic formulations include
docetaxel/cyclophosphamide, doxorubicin/cyclophosphamide, and
cyclophosphamide/methotrexate/5-fluorouracil for lower-risk patients, and doxorubicin/taxane
treatments for higher risk patients (Waks & Winer, 2019). Anthracyclines, a class of
chemotherapeutic drugs including doxorubicin (also known as adriamycin), will be discussed in
greater detail below.
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Finally, immunotherapy represents a newer approach to cancer treatment. Much research

is currently being conducted to develop new immunotherapeutic drugs. As discussed above, a
hallmark of cancer is its ability to evade immune detection. Current approaches have targeted
immune-suppressive proteins produced by tumors as a means of re-sensitizing the immune
system to tumoral antigens (Alsaab et al., 2017; Ernst & Anderson, 2015; Zugazagoitia et al.,
2016). These strategies have met with some success and will surely see more in the coming
years.
1.5. Cancer Treatment and Cell Death
Regardless of modality, the ultimate goal of cancer treatment is to remove and/or kill
cancer cells. Putting aside surgical intervention, all other cancer treatments aim to cause cell
death in some form, of which there are many.
1.5.1. Necrosis. Until the codification of apoptosis in 1972 (Kerr et al., 1972), necrosis
was the only widely recognized form of cell death. In some ways, necrosis is the simplest form
of cell death. Largely unregulated, it is generally caused by excessive stress to the cell in the
form of injury, heat, lack of oxygen, or necrotizing infection. Necrosis is characterized by
multiple breaches in the plasma membrane through which cellular contents can leak out (and
through which other substances can potentially enter) (Lodish et al., 2016).
1.5.1.1. Necroptosis. Necroptosis, a variant of necrosis, is more structured. Necroptosis
is activated when tumor necrosis factor alpha (TNFα) binds to TNFR1, its receptor; it can also be
initiated by other “cell murder” ligand receptor pairs. Receptor binding causes receptor
interacting protein 1 (RIP1) and 3 (RIP3) to form a complex called the necrosome. In the
absence of caspase-8, the initiating caspase related to cell murder processes (discussed in more
detail below), the necrosome complex phosphorylates mixed lineage kinase-like pseudokinase
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membrane, and forming necrotic pores (D’Arcy, 2019; Gong et al., 2019). Necroptosis can be
either pro- or anti-cancer; the process can act as a fail-safe when caspase-8 is nonfunctional, but
it can also cause inflammation that promotes cancer formation and growth (Gong et al., 2019).
1.5.2. Apoptosis. Apoptosis is the most famous form of programmed cell death. As
mentioned above, cells undergoing apoptosis shrink and fragment, and the fragments are taken
up by phagocytic cells for disposal. It is an endergonic, highly ordered process that can be
triggered by a variety of stimuli including DNA damage, detachment from the ECM (also called
anoikis), cell murder signals, or the absence of stimulus by the various trophic factors that cells
require to stay alive, like the testosterone that prostate gland cells require (as in the earlier
example) (Paoli, Giannoni, & Chiarugi, 2013). Once apoptosis is activated, it follows one of two
branches of a prescribed signal cascade involving the cleavage of inactive procaspases to active
caspases. Intrinsic signals—for example, DNA damage—cause the release of cytochrome c from
the mitochondrial intermembrane space. Cytochrome c binds to and activates apoptotic protease
activating factor 1 (APAF1). APAF1 cleaves procaspase-9 to the initiator caspase-9. Caspase-9
then cleaves procaspase-3 to the effector or executioner caspase-3, which causes a signal cascade
that leads to cell death as described above (Lodish et al., 2016). Apoptosis triggered by an
extrinsic signal—for example, binding of a cell murder ligand to its receptor—follows a slightly
different pattern, activating the death inducing signaling complex (DISC). DISC cleaves
procaspase-8 to the initiator caspase-8, which then cleaves procaspase-3 to caspase-3 in the same
manner as caspase-9 (D’Arcy, 2019). On top of the stereotyped manner in which apoptosis
proceeds, it is also regulated by a variety of other proteins, including members of the Bcl-2 and
IAF families of proteins (Lodish et al., 2016).
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1.5.3. Pyroptosis. Apoptosis is not the only form of programmed cell death regulated by

caspase activation. Pyroptosis, inflammation-mediated cell death, is characterized by activation
of caspase-1. Pyroptosis is often caused by a bacterial infection, especially in response to the
bacterial protein flagellin (as well as other proteins of varied provenance). Caspase-1 activation
causes pore formation in the plasma membrane, which allows pyroptotic components to leak into
the extracellular space and stimulate pyroptosis in neighboring cells, causing a chain reaction of
cell death. In fact, pyroptosis may be an attempt to control the spread of bacterial infection, but
the cascade of cell death can also be maladaptive, especially in the setting of chronic sterile
inflammation (Bergsbaken, Fink, & Cookson, 2009).
1.5.4. Autophagy. The last relevant iteration of programmed cell death is autophagy,
literally “self-eating.” As a physiological event, cells utilize autophagy to recycle cell
components for use in new macromolecules or to be broken down further for energy. Cells resort
to autophagy when under stress, especially in starvation conditions when other materials are not
available. Autophagy is initiated by the formation of a concave double membrane structure
within the cytoplasm. The structure grows to engulf a portion of the cytosol, finally closing to
form a vesicle, termed a “phagophore.” The phagophore is trafficked to the lysosome where the
contents can be degraded and used for other purposes (Lodish et al., 2016). In more extreme
cases, autophagy can result in the destruction of the cell; this often occurs to remove old cells
from a larger population, but autophagy is used to destroy early cancer cells as well (D’Arcy,
2019). Malfunctions in the autophagy system can ablate the latter capacity, leading to the growth
of cancers. In fact, beclin-1, a key component to the protein complex that promotes phagophore
formation, is deleted in 40-75% of breast, ovarian, and prostate cancer cases (Mizushima,
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important it is to transforming cancer cells that they avoid death by autophagy.
1.6. Anthracyclines
Even before the many forms of programmed cell death had been described, clinicians had
begun to administer drugs reliant on these processes. Anthracyclines, one such class of
chemotherapeutic drugs, have been used widely since the 1960s for various forms of cancer and
are still among the most effective chemotherapeutics (Minotti, Menna, Salvatorelli, Cairo, &
Gianni, 2004). The first anthracycline discovered, daunorubicin (DNR), was isolated in 1959
from Streptomyces peucetius, a soil bacterium collected in Italy (Di Marco, Cassinelli, &
Arcamone, 1981). Later scientists applied mutagenic agents to S. peucetius, giving rise to a new
subspecies that was able to produce a modified form of DNR that they called adriamycin but is
better known today as doxorubicin (DOX) (Arcamone et al., 1969). Happily, the new drug turned
out to be even more effective at killing cancer cells than the original (Volkova & Russell, 2011).
Anthracyclines induce cell death by interfering with the cell’s replication machinery.
Specifically, they bind tightly to topoisomerase II, the enzyme responsible for relieving tension
brought on by supercoiling during DNA synthesis. The interaction between the anthracycline, the
enzyme, and the DNA strand forms a covalent bond between the double-stranded DNA and the
anthracycline (Marinello, Delcuratolo, & Capranico, 2018). The resulting ternary complex halts
the enzyme’s motion down the DNA strand, causing double-strand breaks and interfering with
DNA synthesis (Binaschi et al., 2001).
As might be expected when administering a drug with such an aggressive mechanism,
anthracyclines have major adverse side effects. Indeed, patients given anthracyclines to treat
cancer exhibit the adverse reactions common to many chemotherapeutics: mucositis,
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nausea/vomiting/diarrhea, alopecia, fatigue, etc. (Ansari et al., 2017). The most concerning side
effect associated with anthracycline treatment, however, is cardiac and skeletal muscle toxicity.
Cardiac damage manifests as congestive heart failure, fibrosis, hypertrophy (Lipshultz et al.,
1991), and arrhythmias (Larsen et al., 1992). Damage is dose-dependent, beginning above a

cumulative dose of 350 mg/m2 body surface area (BSA) and increasing sharply above 550 mg/m2
BSA (Volkova & Russell, 2011). Damage can occur acutely and subacutely, even years after
treatment (Steinherz, Steinherz, Tan, Heller, & Murphy, 1991); one study found that 65% of
patients studied had progressive cardiac anomalies 6 years or more post-treatment (Lipshultz et
al., 1991).
There is some debate as to the exact etiology of the cardiotoxic effects of doxorubicin.
The conjugated ring structure of anthracyclines allows for redox cycling with nearby molecules.
As such, anthracyclines are highly prone to creating radicals in the form of reactive oxygen and
nitrogen species, which can accumulate and cause indiscriminate damage to the cell (Cappetta et
al., 2017). The radical formation hypothesis gains credence from the observation that
mitochondria are especially susceptible to doxorubicin-mediated damage; doxorubicin has a high
binding affinity for cardiolipin, which is concentrated in the inner mitochondrial membrane
(Schlame, Rua, & Greenberg, 2000). However, other evidence argues for the position that
anthracycline cardiotoxicity is due to interactions between anthracyclines and the topoisomerase
IIβ (TopIIβ) isoform, which is prevalent in quiescent cells like (cardio-)myocytes.
Anthracycline-TopIIβ interactions have been observed to cause double-strand DNA breaks and
mitochondrial disturbances within these cells (McGowan et al., 2017). Experiments have
demonstrated that cells depleted of TopIIβ exhibited reduced sensitivity to anthracycline
treatment (Lyu et al., 2007); the same effect appeared in a TopIIβ-deficient mouse model (Zhang
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cause, of anthracycline toxicity.
Regardless of the exact source of cardiotoxicity, researchers have made various attempts
at preventing it. Development of new molecules has been somewhat successful: epirubicin, a
new anthracycline, is as effective as doxorubicin per milligram but can be delivered at twice the
dose while maintaining the same level of toxicity (Robert, 1993). Likewise, encapsulating
doxorubicin in pegylated liposomes reduces the risk of adverse reactions while maintaining
efficacy against cancer (Ansari et al., 2017; Milla, Dosio, & Cattel, 2012). Nevertheless,
cardiotoxicity of these alternative formulations is still relatively high.
Interestingly (given the previous discussion of radical-mediated damage), antioxidants
have garnered interest in preventing damage from radicals. However, they have not seen success
in clinical trials, perhaps because they target the wrong actor (Cappetta et al., 2017). Other
chemicals have shown more promise: in preclinical studies, sildenafil and other
phosphodiesterase 5 (PDE5) inhibitors have been shown to both increase DOX efficacy and
decrease cardiotoxicity (A. Das et al., 2016, 2010), as has beetroot extract (S. Das, Filippone,
Williams, Das, & Kukreja, 2016). Unfortunately, a recent clinical study testing the safety and
efficacy of sildenafil in preventing DOX-mediated cardiotoxicity found that although sildenafil
was safe, it had no effect on important indicators of cardiac function, at least at doses of DOX
below 300 mg/m2 (Poklepovic et al., 2018). Thus, the hunt for cardioprotective drugs continues.
1.7. Exosomes: A New Approach to Cardiotoxicity
The newest frontier in cardioprotection does not involve new chemical formulations but
rather chemotherapeutic treatment in combination with exosome isolates. However, before
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discussing the advantages of exosome treatment, I will first review the recent science regarding
exosome formation and characteristics.
Exosomes are small extracellular vesicles (EVs) between roughly 50 and 150 nm in
diameter (size ranges vary slightly among investigators). They can be differentiated from

microvesicles, another type of small EV, by their expression of specific surface markers, namely
the tetraspanins CD9, CD63, and CD81. Biologically speaking, exosomes are defined by the
process by which they are formed. The precursors of mature exosomes form through
invaginations of the early endosome membrane, which form small intraluminal vesicles (ILVs)
within the endosomal lumen, now termed the multivesicular body (MVB). The exact mechanism
by which ILVs are formed is not clear, although the endosomal sorting complex required for
transport (ESCRT) is known to participate in most (though not all) cases. ILVs within the MVB
can be released as exosomes via fusion of the MVB with the plasma membrane, which ejects the
exosomes into the extracellular space. Alternatively, the MVB can fuse with the lysosome to
recycle the ILVs and their contents (Hessvik & Llorente, 2018; Maas, Breakefield, & Weaver,
2017).
The first researchers to study exosomes hypothesized that the vesicles were used for
cellular waste disposal based on the fact that maturing reticulocytes seemed to be dumping
unnecessary surface proteins via exosome release (Johnstone, Mathew, Mason, & Teng, 1991).
In the years since, EVs (including exosomes) have been found in every biological fluid that has
been tested, and in vitro-grown cell lines have been found to release exosomes into their cell
media (Hessvik & Llorente, 2018). Exosomes contain various macromolecules within their
lumens, including functional mRNA (but no detectable rRNA) (Valadi et al., 2007) and
microRNAs. Exosomes also carry segments of DNA, but their function is unknown (Lázaro-
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those within the mother cell, it is hypothesized that miRNAs are specifically trafficked to
exosomes for export (Wang, Zhang, Weber, Baxter, & Galas, 2010). Exosomal membranes also
contain proteins that serve various purposes, including assisting with docking to recipient cells
(French, Antonyak, & Cerione, 2017).
Since the original reticulocyte studies, it has become clear that the main purpose of
exosomes is cell-to-cell communication. In normal cells, exosomes are important to such diverse
processes as the formation of the neuromuscular junction (Maggio et al., 2019), stem cell
differentiation (Quesenberry, Aliotta, Deregibus, & Camussi, 2015), wound healing (Han, Tran,
Chang, Azar, & Zieske, 2017; Quesenberry et al., 2015), and many others. Exosomes are
important to cancer cell-to-cell communication as well (Al-Sowayan, Al-Shareeda, & AlHujaily, 2019), both within the tumor microenvironment (Wu, Zhou, Lv, Zhu, & Tang, 2019)
and between tumors and distant metastases (Wortzel, Dror, Kenific, & Lyden, 2019). In addition
to exosomes’ apparent importance in communication, they may also play a role in noncommunicative transfer of macromolecules. Exosomes are capable of delivering free fatty acids
to cardiac cells (Garcia et al., 2019), and they may even play a role in waste disposal after all via
autophagy (Gudbergsson & Johnsen, 2019).
Finally, and most relevant to the current study, there is evidence that exosomes can play a
role in cardioprotection. Exosomes derived from embryonic stem (ES) cells are capable of
decreasing ischemia/reperfusion-mediated damage to the heart on a variety of axes (decreased
infarct size, increased angiogenesis, reduced fibrosis and remodeling, improved contractility)
(Davidson & Yellon, 2018). Furthermore, in vitro exosome treatment was shown to decrease
DOX-mediated inflammation and pyroptosis in mouse soleus muscle (Tavakoli Dargani, Singla,
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Johnson, Kukreja, & Singla, 2018). More recent data from our collaborator Dr. Dinender Singla
(University of Central Florida, Orlando) 3 showed that treatment of mice with DOX for 56 days
significantly lowered grip strength. However, treatment with ES exosomes on alternating days

surrounding DOX treatment significantly improved grip strength, rendering mice treated with ES
exosomes indistinguishable from control mice in terms of grip strength. In addition, treatment
with ES exosomes significantly attenuated muscle atrophy as well as pyroptosis caused by DOX
treatment in mice. If the mechanism of anthracycline toxicity is truly the same in cardiac and
skeletal muscle, exosome treatment should have similar mitigatory effects in cardiac tissue as
well. Researchers have even used modified human umbilical cord stem cell-derived exosomes to
treat infarct damage directly (Ni et al., 2019), while others have managed to load mesenchymal
stem cell-derived exosomes with taxol, a chemotherapeutic drug unrelated to DOX or other
anthracyclines, and deliver smaller doses of the drug with high antineoplastic efficacy (Melzer et
al., 2019). Based on these achievements, the future for exosome-based treatment seems limitless.
1.8. The Present Study
The goal of the present study is to test the hypothesis that the addition of exosomes to
doxorubicin treatment does not interfere with the chemotherapeutic effects of doxorubicin. We
will measure the effects of combined exosome/doxorubicin treatment in several ways. We will
examine the treatment’s effect on cell proliferation, cell death generally, and apoptosis
specifically. We will also quantify any changes in levels of proteins important to initiation and
prevention of apoptosis. Finally, we will attempt to determine the effects of
exosome/doxorubicin treatment on EMT using a specific microRNA as a marker. We expect that
the insights arising from the present study will contribute to a better understanding of the
The data referenced here was presented as part of a poster at the Experimental Biology 2019 conference (A. Das
et al., 2019).

3

ES EXOSOMES INCREASE DOX ACTIVITY IN BREAST CANCER

processes that underly previously observed interactions between exosomes, cancer, and cell
death.
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Cell Culture
Cancer cell lines MCF7 (ATCC HTB-22), MDA-MB-231 (ATCC HTB-26), and MDAMB-468 (ATCC HTB-132) were purchased from ATCC. Cells were initially seeded in 25 cm2
(T-25) flasks then transferred to 75 cm2 (T-75) flasks via trypsinization once reaching 80%
confluence. Cells were cultured at 37° C and 5% CO2.
Cell Media and Reagents
All three cell lines were cultured in Dulbecco’s Modified Eagle Media (DMEM) with
high glucose and pyruvate (Gibco) to which 10% Benchmark fetal bovine serum (FBS, Gemini
Bio-Products) and 1% penicillin/streptomycin (10000 U/mL, Gibco) were added. Phosphatebuffered saline (PBS, pH 7.4, 1X) was obtained from Gibco.
Doxorubicin hydrochloride was obtained from Sigma and diluted to 1 μM. Exosomes
isolated from human embryonic stem (ES) cells and mouse embryonic fibroblasts (MEF) at a
concentration of 5 μg/mL were graciously provided by our collaborator Dr. Dinender Singla at
the Burnett School of Medical Sciences at the University of Central Florida.
Microscopy
Cells were visualized using a Nikon Eclipse Ti-S phase contrast microscope. Digital
photographs were obtained using an attached Nikon DS-Fi1 camera controlled by a Nikon DSU3 camera controller and analyzed using the NIS Elements AR software (Nikon, version 3.2).
Doxorubicin/Exosome Treatment
Cells were allowed to grow to 60-80% confluence. Culture medium was removed,
adherent cells were washed with PBS, which was then discarded. New media was added
containing: no additives (control condition); 1 μM doxorubicin hydrochloride (“DOX”
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condition); 1 μM doxorubicin hydrochloride and 10 μg/mL ES exosomes (“DOX+ES”
condition); or 1 μM doxorubicin hydrochloride and 10 μg/mL MEF exosomes (“MEF”
condition). Cells were incubated in treatment media at 37° C and 5% CO2 for 48 hours.
Cell Death Assay
After doxorubicin/exosome treatment, culture medium was aspirated from the growth
flask or plate. Adherent cells were washed with PBS, which was then aspirated and added to the
vessel containing the previously-collected media. Trypsin-EDTA (0.25%, Gibco) was added to
the flask or plate and incubated for five minutes at 37° C and 5% CO2 to detach the cells from
the surface. A portion of the previously-collected media/PBS was added to the cell-trypsin
suspension to inactivate the trypsin. The suspension was aspirated and added back to the vessel
containing the remaining media/PBS mixture. The vessel was centrifuged at 3,000 rcf for 5
minutes to pellet the cells out of solution. The liquid phase was poured off and the pellet was
resuspended in 1 mL of cold PBS. 100 μL of the suspension was removed to a 1.5 mL Eppendorf
tube to which was added 15 μL of trypan blue solution (0.4%, Sigma). 20 μL of the suspension
was pipetted onto a Bright-Line Hemacytometer (Hausser Scientific) and cells in each quadrant
were counted manually using a phase contrast microscope.
Cell Proliferation Assay
Cells were plated on 96-well plates and allowed to grow to 60-80% confluence. Cells
were treated with doxorubicin hydrochloride/exosomes as described above. After the 48 hour
treatment period, media was removed and 110 μL of a 1:5 mixture of CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega) MTS reagent and culture medium was added to
each well. Plates were incubated for 30 minutes at 37° C and 5% CO2. After incubation,
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SoftMax Pro software (version 5).
Flow Cytometry
Cells for flow cytometry were plated in six-well plates. After reaching 80% confluency,
cells were treated with doxorubicin hydrochloride and exosomes, as described above, with two
wells per treatment condition. After 48 hours of treatment, cells were harvested via trypsinization
as described above, keeping harvested cells as close to 0° C as possible. Samples were prepared
from the harvested cells using the Dead Cell Apoptosis Kit with Annexin V Alexa Fluor™ 488
& Propidium Iodide (Invitrogen) according to the manufacturer’s instructions. Samples were
analyzed using a BD FACSCanto II Analyzer in conjunction with the FACSDIVA analysis
software.
Protein Isolation/Quantification
Protein was isolated from pelleted cells post-treatment using Cell Lysis Buffer (10X, Cell
Signaling Technology) with Protease/Phosphatase Inhibitor Cocktail (100X, Cell Signaling
Technology) according to the manufacturer’s instructions. Isolated protein was quantified via
Bradford assay using a SmartSpec 3000 spectrophotometer (Bio-Rad) and Quick Start™
Bradford 1x Dye Reagent (Bio-Rad) in a 500:1 reagent-to-protein dilution.
SDS PAGE
Protein samples were mixed with Laemmli sample buffer (Bio-Rad) in a 1:1 ratio and
boiled at 100° C for 5 minutes to denature the proteins. The lysates were then loaded in precast
4–20% Criterion TGX Protein Gel (Bio-Rad) immersed in Tris/Glycine/SDS Buffer (Bio-Rad)
prepared according to the manufacturer’s instructions. A Dual Color, 10-250 kD Precision Plus
Protein Standard (Bio-Rad) was used to measure protein migration. Gel electrophoresis was
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approximately 50 minutes.
Western Blot
Separated proteins were transferred from the gel to a nitrocellulose membrane (2 μm,
Bio-Rad) immersed in Tris/Glycine Buffer (Bio-Rad), prepared according to the manufacturer’s
instructions. Transfer was accomplished via a 300 mA current over one hour. The membrane was
stained using Ponceau S solution (Sigma-Aldrich) to confirm protein transfer. The membrane
was washed to remove Ponceau stain with 0.1% TWEEN 20 (Sigma) in Tris-buffered saline
(TBS, Bio-Rad), prepared according to the manufacturer’s instructions. The membrane was
developed according to a general Western blot protocol from Abcam. The membrane was
incubated with antibodies for Bax (D2E11, Cell Signaling Technologies), Bcl-2 (D55G8, Cell
Signaling Technologies), and GAPDH (14C10, Cell Signaling Technologies) in a 5% w/v bovine
serum albumin (BSA, Sigma), 0.1% TWEEN 20 TBS solution at a dilution recommended by the
manufacturer for each antibody. The membrane was further incubated in anti-mouse or antirabbit IgG, horse radish peroxidase (HRP)-linked antibodies (Cell Signaling Technologies)
appropriate to the given primary antibody as per the manufacturer’s instructions.
Blots were visualized using one of two methods. One portion was visualized using
Western Lightning Plus-ECL Enhanced Chemiluminescence Substrate (PerkinElmer) as a
chemiluminescent reagent to expose radiographic film (BioExcell autoradiographic film,
WorldWide Medical Products). The exposed film was developed using a Kodak X-OMAT
2000A processor. The other portion of blots was visualized using Clarity Western ECL Substrate
(Bio-Rad) and a ChemiDoc XRS+ imaging system (Bio-Rad). The images were processed with

ES EXOSOMES INCREASE DOX ACTIVITY IN BREAST CANCER

the ImageLab software (Bio-Rad). Blot images were analyzed using ImageJ (Rueden et al.,

30

2017).
RNA Isolation
Treated cells were collected via trypsinization and flash-frozen in liquid nitrogen. Total
RNA, including small RNA, was isolated from the samples using the miRNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. The concentration and purity of the
isolated RNA was measured using a NanoDrop One microvolume UV-Vis spectrophotometer
(Thermo Scientific).
cDNA Library Preparation and RT-PCR
CDNA of micro-RNA (miRNA) present in the isolated RNA was synthesized using the
microRT reverse transcription kit (Applied Biosystems). 10 ng of total RNA was subjected to
reverse complement strand synthesis with microRNA-specific stem-loop primers according to
the manufacturer’s instructions. Reverse transcription polymerase chain reaction was conducted
on a CFX96-C1000 Touch Real-Time PCR Detection System (Bio-Rad) using the following
conditions: 16° C for 30 minutes; 42° C for 30 minutes; and 85° C for 5 minutes.
Expression of miR-200c was quantified via real-time PCR (RT-PCR) using ampliconspecific Taqman assay probes and primers (Applied Biosystems) using a CFX96-C1000 Touch
Real-Time PCR Detection System. Conditions for the RT-PCR run were as follows: 50° C for 2
minutes; 95° C for 3 seconds; 60° C for 39 cycles of 1 minute per cycle. The small nucleolar
RNA sno-202, a housekeeping snoRNA, was used to normalize miRNA expression.
MiRNA relative quantification data obtained from RT-PCR was analyzed using the 2ΔΔCT

method and normalized to the sno-202 control.
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Data are reported as mean or mean ± standard error of the mean (SEM). One-way
ANOVA followed by Tukey’s multiple comparisons test was performed using GraphPad Prism
version 8.1.2 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.
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In the present study, we used three cancer cell-lines for studying the effect of embryonic
stem (ES) cell-derived exosomes on doxorubicin hydrochloride (DOX)-induced cell killing.
These cell lines were MCF7, MDA-MB-231 and MDA-MB-468. MCF7 are ER- and PGRpositive but HER2-negative and are a model for hormone therapy. MDA-MB-231 and MDAMB-468 are triple negative and are a model for chemotherapy. Exosomes were administered at a
concentration of 10 μg/mL based on the results of cell viability assays comparing the
antiproliferative effects of 5 μg/mL, 10 μg/mL, and 20 μg/mL concentrations (below, Figures 6ac). The assays showed no significant difference between the three concentrations in terms of
antiproliferative effects, on cells from either the MCF7 or MDA-MB-231 cell lines. Although a
higher dose of exosomes was associated with a trend of increased antiproliferative activity in the
MCF7 cells, the MDA-MB-231 cells responded to an increased dose of exosomes with a Ushaped trend, where the 10 μg/mL concentration exhibited the largest antiproliferative effect. As
such, the 10 μg/mL concentration was chosen for this study.
3.1. Cell Death Assay with Trypan Blue
Exosome/DOX treatment increases overall cell death. Treatment of MCF7 cells with
DOX/ES exosomes for 48 hours significantly increased cell death (31.9 ± 1.3% cell death, n=4)
compared to control (6.2 ± 1.1% cell death, n=4, p<0.0001) and compared to DOX alone (22.9 ±
0.3% cell death, n=4, p=0.002). Cell death was also significantly increased after treatment with
DOX/MEF for 48 hours (15.2 ± 2.4% cell death, n=4) compared to control (p=0.002) (Figure
1a).
Treatment of MDA-MB-231 cells with DOX/ES exosomes for 48 hours significantly
increased cell death (49.2 ± 2.0% cell death, n=4) compared to control (11.4 ± 0.01% cell death,
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n=4, p<0.0001) and compared to DOX alone (38.2 ± 1.2% cell death, n=4, p<0.0001). Cell death
was also significantly increased after treatment with DOX/MEF for 48 hours (42.2 ± 0.5% cell
death, n=4) compared to control (p<0.0001) but was not significantly different from DOX alone
(p=0.13) (Figure 1b).
3.2. Flow Cytometry with Annexin V/Propidium Iodide
Exosome/DOX treatment increased overall cell death. Treatment of MCF7 cells with
DOX/ES for 48 hours decreased the number of viable cells and therefore increased the number

of dead cells: 72.0% viable cells versus 85.1% viable cells under the control condition and 75.9%
viable cells under DOX-only treatment. Treatment with DOX/MEF also decreased the number of
viable cells (69.8% viable cells). We counted 10,000 cells for each experimental condition
(Figure 2).
Treatment of MDA-MB-231 cells with DOX/ES for 48 hours decreased the number of
viable cells: 44.2% viable cells (of 3,807 cells counted) versus 91.4% viable cells under the
control condition (of 6,102 cells counted) and 53.5% viable cells under DOX-only treatment (of
3,660 cells counted). Treatment with DOX/MEF also decreased the number of viable cells
(45.5% viable cells of 4,067 cells counted) (Figure 3).
Treatment of MDA-MB-468 cells with DOX/ES for 48 hours decreased the number of
viable cells: 71.6% viable cells versus 95.3% viable cells under the control condition and 80.9%
viable cells under DOX-only treatment. Treatment with DOX/MEF also decreased the number of
viable cells (57.7% viable cells). We counted 10,000 cells for each experimental condition
(Figure 4).
Exosome/DOX treatment increased apoptosis. Treatment of MCF7 cells with DOX/ES
for 48 hours increased early apoptosis, as measured by the percentage of cells with coordinates in
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only. Treatment with DOX/MEF also increased early apoptosis to 11.2%. Note that the number
of cells counted are reported in the previous section (Figure 2).
Treatment of MDA-MB-231 cells with DOX/ES for 48 hours increased early apoptosis,
as measured by the percentage of cells with coordinates in quadrant 4: 40.1% versus 6.4% under
the control condition and 31.1% when treated with DOX only. Treatment with DOX/MEF also
increased early apoptosis to 41.0% (Figure 3).
Treatment of MDA-MB-468 cells with DOX/ES for 48 hours increased early apoptosis,
as measured by the percentage of cells with coordinates in quadrant 4: 22.1% versus 2.6% under
the control condition and 13.7% when treated with DOX only. Treatment with DOX/MEF also
increased early apoptosis to 35.9% (Figure 4).
3.3. MTS Cell Proliferation Assay
Exosome/DOX treatment increases or maintains DOX antiproliferative effects.
Proliferation of MCF7 cells treated with DOX/ES exosomes for 48 hours (43.2 ± 1.2% viable
cells, n=6) was significantly lower than control (100.0 ± 3.3% viable cells, n=10, p<0.0001) and
DOX alone (62.2 ± 4.4% viable cells, n=12, p=0.006). Proliferation of MCF7 cells treated with
DOX/MEF exosomes (31.8 ± 3.3% viable cells, n=6) was significantly lower than control
(p<0.0001) and DOX alone (p<0.0001) (Figure 6a).
Proliferation of MDA-MB-231 cells treated with DOX/ES exosomes for 48 hours (25.6 ±
0.7% viable cells, n=6) was significantly lower than control (100.0 ± 2.8% viable cells, n=10,
p<0.0001) but did not differ from cells treated with DOX alone (25.8 ± 0.5% viable cells, n=12,
p>0.99). Proliferation of MDA-MB-231 cells treated with DOX/MEF exosomes (23.4 ± 0.9%
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treated with DOX alone (p>0.99) (Figure 6b).
Proliferation of MDA-MB-468 cells treated with DOX/ES exosomes for 48 hours (60.1 ±
1.7% viable cells, n=16) was significantly lower than control (100.0 ± 5.0% viable cells, n=14,
p<0.0001) but did not differ from cells treated with DOX alone (53.3 ± 1.6% viable cells, n=14,
p=0.96). Proliferation of MDA-MB-468 cells treated with DOX/MEF exosomes (53.1 ± 1.3%
viable cells, n=16) was significantly lower than control (p<0.0001) but did not differ from cells
treated with DOX alone (p>0.99) (Figure 6c).
3.4. Real-Time Polymerase Chain Reaction
Treatment with DOX/Exosomes Decreases expression of miR-200c. Treatment of
MCF7 cells with DOX/ES exosomes for 48 hours decreased expression of miR-200c, a 0.77-fold
change compared to control (± 0.05, n=3, p=0.36). Expression was also decreased compared to
DOX alone (1.02 ± 0.05-fold change compared to control; p=0.24). Treatment with both ES
exosomes alone and with DOX/MEF exosomes produced significant changes compared to both
control (ES: 0.65 ± 0.07-fold change, p=0.033; DOX/MEF: 0.63 ± 0.05-fold change, p=0.02) and
DOX alone (ES: p=0.02; DOX/MEF: p=0.01) (Figure 7a).
Treatment of MDA-MB-231 cells with DOX/ES exosomes for 48 hours did not decrease
expression of miR-200c, a 0.89-fold change compared to control (± 0.03, n=3, p=0.89), but
likely did decrease expression compared to DOX alone (1.13 ± 0.07-fold change compared to
control; p=0.29). Treatment with ES exosomes alone also may have decreased expression
compared to control (0.81 ± 0.11-fold change, p=0.48) and likely decreased expression compared
to DOX alone (p=0.09) (Figure 7b).
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decreased expression of miR-200c, a 0.55-fold change compared to control (± 0.05, n=3,
p=0.01). Expression may have also decreased compared to DOX alone (0.71 ± 0.7-fold change
compared to control; p=0.66) (Figure 7c).

3.5. Western Blot
Exosome/doxorubicin treatment increased Bax expression. Treatment of MCF7 cells
with a combination of doxorubicin hydrochloride (DOX) and embryonic stem cell-derived (ES)
exosome solution (DOX/ES) for 48 hours caused an appreciable increase in expression of Bax
(mean relative density: 1.51, n=2) compared to control (mean relative density: 1.00) and a
possible increase compared to treatment with DOX alone (mean relative density: 1.39).
Treatment with mouse embryonic fibroblast-derived (MEF) exosomes in combination with DOX
(DOX/MEF) also caused an appreciable increase in Bax expression (mean relative density: 1.59,
n=2) compared to control and a noticeable increase compared to treatment with DOX alone
(Figure 8a).
Treatment of MDA-MB-231 cells with DOX+ES under the same conditions also appeared to
increase the expression of Bax (mean relative density: 1.35, n=2) compared to control (mean
relative density: 1.02) (Figure 9a).
Exosome/doxorubicin treatment decreased Bcl-2 expression. Treatment of MCF7
cells with DOX and ES exosomes as above caused a slight decrease in the expression of Bcl-2
(mean relative density: 0.83, n=2) compared to control (mean relative density: 1.00) and
treatment with DOX alone (mean relative density: 0.98) (Figure 8b).

ES EXOSOMES INCREASE DOX ACTIVITY IN BREAST CANCER

37

Treatment of MDA-MB-468 cells with DOX/ES exosomes caused a decrease in the expression
of Bcl-2 (mean relative density: 0.73, n=2) compared to control (mean relative density: 1.00);
there was no change compared to DOX alone (mean relative density: 0.71). Treatment with
DOX+MEF also caused a decrease in Bcl-2 (mean relative density: 0.75, n=2) compared to
control but likely no change compared to treatment with DOX alone (Figure 10b).
Exosome/doxorubicin treatment increased expression of Bax compared to Bcl-2.
Treatment of MCF7 cells with DOX/ES increased the expression of Bax compared to Bcl-2
(when expressed as a ratio of Bax/Bcl-2; mean relative density: 1.82) versus control (mean

relative density: 1.00). Expression of Bax versus Bcl-2 was also noticeably increased compared
to DOX alone (mean relative density: 1.44). Treatment with MEF/DOX also increased the
expression of Bax versus Bcl-2 (1.76) compared to control and was increased compared to
treatment with DOX alone (Figure 8c).
Treatment of MDA-MB-231 cells with ES/DOX increased expression of Bax versus Bcl2 (mean relative density: 1.40, n=2) compared to control (mean relative density: 1.00).
Expression was not changed compared to treatment with DOX alone (mean relative density:
1.39) (Figure 9c).
Treatment of MDA-MB-468 cells with ES/DOX did not clearly increase expression of
Bax versus Bcl-2 (mean relative density: 1.07, n=2) compared to control (mean relative density:
1.00) nor when compared to DOX alone (mean relative density: 1.22). Likewise, treatment with
MEF/DOX did not clearly increase the expression of Bax versus Bcl-2 (mean relative density:
1.36) compared to control or compared to treatment with DOX alone (Figure 10c).
Treatment with exosomes alone did not change measured protein expression.
Treatment of MCF7 cells for 48 hours with ES exosomes alone did not change Bax expression
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compared to control (mean relative density: 1.05 vs. 1.00, n=2) or Bcl-2 expression compared to
control (mean relative density: 1.13 vs. 1.00, n=2) (Figure 8a). Likewise, treatment with MEF

exosomes alone did not change Bax expression compared to control (mean relative density: 1.09
vs. 1.00, n=2) or Bcl-2 expression compared to control (mean relative density: 1.07 vs. 1.00,
n=2) (Figure 8b). The ratio of Bax to Bcl-2 expression was not altered by treatment with ES
alone compared to control (mean relative density: 0.93 vs. 1.00, n=2) or by treatment with MEF
alone compared to control (mean relative density: 1.03 vs. 1.00, n=2) (Figure 8c).
Treatment of MDA-MB-231 cells for 48 hours with ES exosomes alone did not change
Bax expression compared to control (mean relative density: 1.08 vs. 1.02, n=2) or Bcl-2
expression compared to control (mean relative density: 1.07 vs. 1.01, n=2) (Figure 9a).
Treatment with MEF exosomes alone also did not change Bax expression compared to control
(mean relative density: 0.93 vs. 1.02) or Bcl-2 expression compared to control (mean relative
density: 1.01 vs. 1.01, n=2) (Figure 9b). The ratio of Bax to Bcl-2 expression was not altered by
treatment with ES alone compared to control (mean relative density: 0.99 vs. 1.00, n=2) or by
treatment with MEF alone compared to control (mean relative density: 0.92 vs. 1.00, n=2)
(Figure 9c).
Treatment of MDA-MB-468 cells for 48 hours with ES exosomes alone did not increase
and may have decreased Bax expression compared to control (mean relative density: 0.77 vs.
1.00, n=2) (Figure 10a) and did not change Bcl-2 expression compared to control (mean relative
density: 0.98 vs. 1.00, n=2) (Figure 10b). Treatment with MEF exosomes alone also did not
increase and may have decreased Bax expression compared to control (mean relative density:
0.81 vs. 1.00, p=0.049) and did not change Bcl-2 expression compared to control (mean relative
density: 1.03 vs. 1.00, n=2). The ratio of Bax to Bcl-2 expression was not increased and may
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0.79 vs. 1.00, n=2) and by treatment with MEF alone compared to control (mean relative density:
0.79 vs. 1.00, n=2) (Figure 10c).
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Doxorubicin (DOX) is one of the most widely used chemotherapeutic drugs. It is very
effective at treating a wide range of cancers, in particular breast and esophageal cancers,
osteosarcoma, Kaposi’s sarcoma, soft tissue sarcomas, and both Hodgkin’s and non-Hodgkin’s
lymphomas (Singal & Iliskovic, 1998). However, the use of DOX in cancer treatment is limited
by its dose-dependent cardiotoxicity. As noted in the introduction, a cumulative dose of 350
mg/m2 of body surface area (BSA) causes cardiotoxic effects to begin to quickly increase; above
500 mg/m2 BSA, the risk of adverse effects on the heart increases to unacceptable levels. High
concentrations of DOX carry a high risk of congestive heart failure (CHF), dilated
cardiomyopathy, and death (Singal, Deally, & Weinberg, 1987; Singal & Iliskovic, 1998).
Because there is no effective treatment for DOX-induced cardiotoxicity, patients treated with
high doses of DOX have a poor prognosis. DOX is also harmful to skeletal muscle, causing
muscle fatigue and weakness. However, recent data from our lab has produced encouraging
results, showing a cytoprotective effect of embryonic stem cell-derived (ES) exosomes on DOXinduced inflammation and pyroptosis in Sol-8 slow-twitch soleus muscle cells (Tavakoli Dargani
et al., 2018). Furthermore, unpublished data from our collaborator Dr. Dinender K Singla
(University of Central Florida) showed improved muscle grip strength in mice following
alternating treatments with DOX and ES exosomes. Although these data suggest that ES
exosomes may have a significant cytoprotective effect, the effect of ES exosomes on cancer cells
is not known. Therefore, the present study sought to investigate whether the addition of ES
exosomes contributed to the killing of cancer cells by DOX treatment.
Our results showed that DOX/ES exosome treatment of cancer cells either increased or
maintained the cell killing and antiproliferative effects of DOX alone. Western blot analysis
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showed a marked increase in Bax compared to Bcl-2 in cells treated with a combination of ES or
mouse embryonic fibroblast (MEF) exosomes and DOX compared to control across all three cell
lines studied, and compared to DOX alone for the MCF7 cell line. These results suggest that
DOX/ES exosomes treatment increases apoptosis across these cell lines.

As discussed in the introduction, cell death comes in many forms; the most relevant to the
present study is apoptosis. Apoptosis can result from either intrinsic or extrinsic signals.
Intrinsically mediated apoptosis occurs when cytochrome c is released from the mitochondrial
intermembrane space and activates APAF-1, causing a signaling cascade that results in cell
death. Many signals can liberate cytochrome c; one such signal is the activation of the proapoptotic protein Bax, which forms oligomers that insert into the mitochondrial outer membrane
and form a pore often referred to as the mitochondrial permeability transition pore (MPTP). Bcl2, an anti-apoptotic protein, maintains the mitochondrial outer membrane’s low permeability by
binding to and sequestering Bax (Lodish et al., 2016, p. 1018). Thus, disruption of the Bcl-2/Bax
interaction can precipitate apoptosis, as can overexpression of Bax or knockdown or deletion of
bcl-2.
To measure apoptosis, we employed several experimental techniques. First, we
performed cell death assays with trypan blue, a type of dye exclusion assay. This assay does not
measure apoptosis directly; instead, it measures total cell death, which combines necrosis,
apoptosis, and any other forms of cell death. The assay takes advantage of a property of all dead
cells, namely the loss of membrane integrity that occurs upon death. Living cells tightly regulate
their membrane permeability. Only very specific materials are allowed to pass across the
membrane into the cytoplasm. When a cell dies, however, the mechanisms that govern this strict
control unravel, and the membrane develops holes. Trypan blue, a water-soluble blue dye, can
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under a microscope (Strober, 2001). The number of living and dead cells can then be manually
counted and the total amount of cell death can be obtained. In accordance with the protein
expression data discussed above, cell death increased significantly in cells treated with DOX/ES
exosomes compared to control as well as compared to DOX alone across both the MCF7 and
MDA-MB-231 cell lines (Figures 1a and b). Again, the assay results encompass all kinds of cell
death and not solely apoptotic cell death. Even so, the results should be consistent with other
measures of cell death or apoptosis, assuming that other forms of cell death besides apoptosis are
not a large source of variability within the bounds of the DOX/ES exosomes treatment paradigm.
Like the cell death assays discussed above, cell proliferation assays also indicated that
treatment with DOX/ES exosomes contributed to the larger cell killing effect compared to DOX
alone. The cell proliferation assays performed as part of this study differ from cell death assays
in that they measure cell metabolism, not cell death. To assay for cell proliferation, cells were
grown in a 96-well plate. Once the cells reach appropriate confluence, an MTS 4 solution was
added to the cell media and the cells were incubated for a short time. During incubation, healthy
cells broke down the MTS substrate, forming a formazan dye that caused the cell media to
change color in a manner proportionate to the amount of dye formed. The resulting color change
was then measured using a microplate reader.
Like the cell death assays, the cell proliferation assays showed a decrease in cell activity
for cells treated with DOX/ES exosomes compared to control across the MCF7, MDA-MB-231,
MDA-MB-468 cell lines (Figures 6a-c). However, only the MCF7 cells showed a different
response to the DOX/ES exosomes treatment and DOX treatment alone. The cell death assays, as

4

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
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efficacy of the DOX/ES exosomes treatment over DOX alone for the MCF7, MDA-MB-231, and
(in the case of the flow cytometry data) MDA-MB-468 cell lines. Especially because of the large
difference in DOX growth suppression between the MCF7 and MDA-MB-231 cell lines in the
cell proliferation data (43% viable MCF7 cells versus 26% viable MDA-MB-231 cells under the
DOX/ES exosome condition), future experiments will be performed to validate the observation
that MDA-MB-231 proliferation is equally suppressed by treatment with DOX/ES exosomes and
DOX alone. What is more puzzling is the fact the DOX/ES exosomes and DOX/MEF exosomes
treatments had the same effect on cell proliferation for all three cell lines. In this case, the cell
proliferation data agreed with both the flow cytometry and protein expression data as discussed
above, neither of which showed a distinct difference between the DOX/ES and DOX/MEF
exosomes treatments. The similarity in effects of ES and MEF exosomes across experiments will
be discussed in depth below; suffice it to say until that discussion that the differences between
the new exosome populations needs to be characterized more fully.
As mentioned above, our results from the flow cytometry experiments showed increased
cell death, similar to the results of the cell death assays. However, unlike a simple dye exclusion
assay, flow cytometry can separate cells by type of cell death—here, necrosis versus apoptosis—
as well as a host of other characteristics.
To assess cell necrosis or apoptosis using flow cytometry, two dyes were added to the
cell suspension, one that binds to all dead cells and another that binds only to apoptotic cells. The
first, propidium iodide (PI), is a fluorescent dye that binds tightly to nucleotides by intercalating
between bases. As explained in the introduction, during later stages of cell death, the nuclear
envelope disintegrates and genetic material is broken into fragments. In addition, cell death
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nucleic acid fragments, much the same way that trypan blue enters dead cells during a dye
exclusion assay (Nicoletti, Migliorati, Pagliacci, Grignani, & Riccardi, 1991; Riccardi &
Nicoletti, 2006). Because PI is fluorescent, the amount of the dye in each cell can be quantitated
individually by a flow cytometer and each measurement can be graphed along an axis of healthy
to necrotic cells.
Although later stages of apoptosis can disrupt the integrity of the cell membrane, cells in
the early stages of apoptosis have intact cell membranes. However, as the apoptotic process
progresses, the membrane begins to change and phosphatidyl serine (PS), a membrane lipid,
translocates from the inner leaflet to the outer leaflet (Vermes, Haanen, Steffens-Nakken, &
Reutellingsperger, 1995). To measure the extent of PS translocation, annexin V, an antibody
specific for PS, is added to the cell suspension. For the flow cytometry experiments, the annexin
V antibodies are conjugated with a fluorescent protein that fluoresces at a different wavelength
than PI, allowing signals from PI and annexin V to be separated from one another. Like the data
obtained from PI staining, the annexin V data can be graphed along an axis from healthy cells to
apoptotic cells. When the data from both dyes is combined into a single graph, cells with low
annexin V and high PI signals can be assumed to be necrotic (and fall into quadrant 1); cells with
high annexin V and low PI signals can be assumed to be in the early stages of apoptosis (and fall
into Q4); and cells with high fluorescence from both dyes can be assumed to be in the late stages
of necrosis.
The flow cytometry data showed that overall cell death increased due to DOX/ES
exosomes treatment (Figures 2-4), which was congruent to the results of the cell death (dye
exclusion) assays. Furthermore, cell death increased specifically as a result of increased
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control populations or those treated with DOX alone. These results suggest that the addition of
exosomes did not increase necrosis directly. Indeed, there has not been any evidence to show that
exosome treatment should increase necroptosis. These experiments did not make a distinction
between necrosis and pyroptosis or autophagy. However, the large increase in apoptosis suggests
that inflammation could be playing an important role in ES exosomes-induced increases in the
cell-killing power of DOX. Further studies are needed to fully understand the mechanisms of
early increase in apoptosis following treatment with DOX plus ES exosomes.
In addition to studying the effects of exosome treatment on cell proliferation and death,
we also examined the role of exosomes in altering the expression of regulatory RNAs in cancer
cells. Specifically, we looked at the expression of microRNAs (miRNAs), small (~22 nucleotide)
strands of RNA that regulate protein translation, among other processes. To understand the
significance of miRNAs to the cell, it is first important to understand their biogenesis. A segment
of DNA that encodes a specific miRNA is transcribed to a pri-miRNA, a piece of RNA that
ranges in length from hundreds to thousands of nucleotides (nt). The pri-miRNA remains in the
nucleus, where an RNase III-family nuclease called Drosha cleaves it to a ~70 nt precursor
miRNA (pre-miRNAs). The pre-miRNA assumes a hairpin configuration because of the
palindromic sequence of the nucleotides. The pre-miRNA is then exported out of the nucleus to
the cytoplasm via the RanGTP/exportin 5 system. In the cytoplasm, the pre-miRNA is processed
into the mature ~22 nt miRNA by an enzyme called Dicer (Denli, Tops, Plasterk, Ketting, &
Hannon, 2004). Finally, the mature miRNA is activated when it is loaded onto the Argonaute
(Ago) binding protein, which forms the RNA-induced silencing complex (RISC). The complete
RISC can then bind to target mRNA. Depending on the extent of the homology between the
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miRNA sequence and the target, the bound miRNA can either inhibit translation, knocking down

levels of the resulting protein, or lead to outright mRNA cleavage and destruction (Guo & Wang,
2019).
In the current study, we looked specifically at miRNAs belonging to the miR-200 cluster.
This family includes miR-200a, -200b, -200c, miR-141, and miR-429 (Gregory et al., 2008). The
miR-200 family targets ZEB1 and ZEB2 (zinc finger E box-binding homeobox 1 and 2), genes
that code for transcription factors which negatively regulate the E-cadherin promoter (Korpal,
Lee, Hu, & Kang, 2008). The interactions between the miR-200 family, ZEB1/2, and E-cadherin
are heavily implicated in the epithelial-mesenchymal transition (EMT) process: cellular levels of
E-cadherin play a large role in the initiation of EMT, which can contribute to many processes
including embryonic development, wound healing, and cancer metastasis.
Of the members of the miR-200 family, our results showed that miR-200c was most
affected by treatment with DOX/ES exosomes (Figures 7a-c). Although all members of the miR200 family interact with ZEB1/2, each has its own nuances. MiR-200c targets transcripts for both
ZEB1 and ZEB2 (Gregory et al., 2008). In turn, ZEB1 is capable of negatively regulating not
only E-cadherin but also miR-200c. As such, the observed decrease in miR-200c could
potentially lead to a feed-forward effect whereby expression of ZEB1/2, free from miR-200c
repression, increases. The increase in ZEB1 could then cause a decrease in E-cadherin; at the
same time, increased ZEB1 could also cause a further decrease in transcription of miR-200c
(Berx & van Roy, 2009). Therefore, a decrease in miR-200c should lead to an increase in EMT.
However, our results showing a decrease of miR-200c following treatment with
DOX/ES exosomes treatment is not consistent with the other observations. First, EMT is
normally associated with later-stage, deadlier cancers (Otsuki, Saya, & Arima, 2018). EMT—
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resistance in pancreatic cancer (Arumugam et al., 2009), and EMT is associated with worse
clinical outcomes in breast cancer (Teschendorff, Journée, Absil, Sepulchre, & Caldas, 2007).
Furthermore, studies of murine mammary cell lines (Robson, Khaled, Abell, & Watson, 2006)
and cancer cells (Siegel & Massagué, 2003; Thiery, 2002) associated EMT with resistance to
apoptosis. However, results from the cell growth/death experiments showed an increase in
apoptosis (and therefore a decrease in chemotherapeutic drug resistance) as a result of DOX/ES
exosomes treatment, in contrast to previously published work. As such, more work is needed to
verify the observed increase in miR-200c after DOX/ES exosomes treatment and to characterize
the effect of miR-200c on EMT. Also, further studies are required to investigate whether ZEB1
was increased in parallel to the decrease in miR-200c, through quantification of either the ZEB1
protein via Western blot or ZEB1 mRNA via real time PCR (RT-PCR). E-cadherin levels should
also be interrogated directly, again either via Western blot of the protein or RT-PCR of the
mRNA.
The other unexpected finding of this study was the lack of any clear difference in cellkilling efficacy of ES and MEF exosomes. In fact, some of our results showed that the MEF
exosomes were more effective than the ES exosomes at stunting cell growth or inducing
apoptosis (Figures 2, 4, 6a, 6c). It was expected that the human embryonic stem cell-derived
exosomes would be effective against three human cancer cell lines under study while the MEF
exosomes would not, due to differences in molecular composition as well as differences in
species of origin, i.e. human versus mouse. Further extensive characterization of the exosomes
derived from ES cells and MEF is needed to resolve this issue.
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their molecular cargo and their shape and size. First, exosomes are known to carry various forms
of genetic material, including mRNA, miRNA, and DNA (Jabalee, Towle, & Garnis, 2018;
Lázaro-Ibáñez et al., 2014; Valadi et al., 2007). To characterize experimental exosomes, RTPCR could be used to quantify additional miRNAs, including the other members of the miR-200
family, as well as mRNA and possibly even exosomal DNA. RT-PCR gives a necessarily narrow
window on the exosomal “genome” because it requires selection of primers for individual
nucleic acids of interest. However, it can still be a useful tool to explore nucleic acids related to
specific phenomena like apoptosis or EMT. Total RNA sequencing would represent a more
holistic approach to exploring exosomal genetic material, although the technique also requires
sophisticated bioinformatics techniques to glean useful data.
In addition to exploring differences in genetic material among exosome populations, it
would also be useful to further explore exosomal proteins, especially those specific to the
functions of the exosomes themselves. Tetraspanins, a class of transmembrane protein, are
commonly used as markers for detection of exosomes, especially the tetraspanins CD9, CD63,
and CD81 (Lai et al., 2010). Although specific tetraspanin populations do seem to uniquely
characterize exosomes, other proteins may be more important to docking and cargo transfer to
recipient cells. In particular, ECM proteins such as laminin, fibronectin, ICAM-1, and VCAM-1,
and various proteoglycans seem to be important to determine to which specific cell types
exosomes can dock as well as to which tissues exosomes will localize in vivo (French et al.,
2017). Characterization of these proteins may give insight into specific similarities between the
ES and MEF exosomes, as well as details into their interactions with cancer cells. Such
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proteomics of the entire exosome “proteome.”
While genetic material or functional proteins can be used to differentiate between
exosomes, it is equally important to be able to distinguish exosomes from other extracellular
vesicles (EVs). Cells release many types of EVs that differ in size and composition. Especially in
conjunction with molecular analysis, measurements of the size and shape of experimental EVs
are important to confirming the identity of these particles as exosomes. To measure the size of
exosomes and other small vesicles, nanoparticle tracking analysis (NTA) is an effective and
simple technique. NTA uses laser light scattering to track particles’ Brownian motion, allowing
one to accurately count and size EVs down to a diameter of ~50 nm (Carnell-Morris, Tannetta,
Siupa, Hole, & Dragovic, 2017). Matching the measured sizes of EVs in solution to reported data
would help confirm the validity of any results of experiments involving exosomes. Likewise,
electron microscopy can be used to visualize exosome size as well as shape. Although exosomes
had been thought to be cup-shaped or concave, analogous to a deflated basketball, newer
evidence suggests that any concavity was due to distortion and that exosomes are in fact nearperfect spheres (Chernyshev et al., 2015). If EVs used in experimentation are indeed exosomes,
electron microscopy should validate their shape.
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In summary, we have demonstrated that ES exosomes enhance the cytotoxic and growthsuppressing effect of DOX in breast cancer cells. In the future, this finding may potentially
translate to enhancement of DOX’s anti-tumor properties. While several issues related to the
mechanism of cell killing need to be resolved—in particular the role of ES exosomal miR-200family miRNAs—our results appear promising for the potential used of ES exosomes to
attenuate not only DOX-induced cardiotoxicity but also muscle atrophy and dysfunction
associated with chemotherapy. Moreover, studies on the beneficial effects of stem cell-derived
exosomes in health and disease is a growing area of investigation which has the significant
advantage of being inherently cell-free. Therefore, stem cell-derived exosomes may be attractive
for future therapeutic options in cancer chemotherapy.
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7. Appendix

7.1. Cell Death Assay Data
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Figure 1a. Cell death in MCF7 cancer cells, measured via trypan blue dye exclusion assay 48
hours following treatment.
Figure 1b. Cell death in MDA-MB-231 cancer cells, measured via trypan blue dye exclusion
assay 48 hours following treatment.
Abbreviations: DOX: Doxorubicin; ES: Embryonic stem cell; MEF: Mouse embryonic
fibroblasts.
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Figure 2. Apoptosis and necrosis of MCF7 cells 48 hours following treatment. Percentages
indicate percent of total cells counted in each quadrant. Q1: Necrotic cells. Q2: Late-stage
apoptotic cells. Q3: Viable cells. Q4: Early-stage apoptotic cells. X-axis represents annexin V
intensity; y-axis represents propidium iodide intensity. Abbreviations: DOX: Doxorubicin; ES:
Embryonic stem cell; MEF: Mouse embryonic fibroblasts.
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Figure 3. Apoptosis and necrosis of MDA-MB-231 cells 48 hours following treatment.
Percentages indicate percent of total cells counted in each quadrant. Q1: Necrotic cells. Q2: Latestage apoptotic cells. Q3: Viable cells. Q4: Early-stage apoptotic cells. X-axis represents annexin
V intensity; y-axis represents propidium iodide intensity. Abbreviations: DOX: Doxorubicin; ES:
Embryonic stem cell; MEF: Mouse embryonic fibroblasts.
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Figure 4. Apoptosis and necrosis of MDA-MB-468 cells 48 hours following treatment.
Percentages indicate percent of total cells counted in each quadrant. Q1: Necrotic cells. Q2: Latestage apoptotic cells. Q3: Viable cells. Q4: Early-stage apoptotic cells. X-axis represents annexin
V intensity; y-axis represents propidium iodide intensity. Abbreviations: DOX: Doxorubicin; ES:
Embryonic stem cell; MEF: Mouse embryonic fibroblasts.
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Table 1. Flow cytometry distributions. “Viable” refers to cells in quadrant 3, “early apoptosis” to
cells in quadrant 4, “late apoptosis” to cells in quadrant 2, and “necrosis” to cells in quadrant 1.
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Figure 5a. MCF7 cell line. Graphical representation of the flow cytometry distributions
presented in Table 1.
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Figure 5b. MDA-MB-231 cell line. Graphical representation of the flow cytometry
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Figure 5c. MDA-MB-468 cell line. Graphical representation of the flow cytometry
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7.3. Cell Proliferation Assay Data
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Figure 6a. MTS assay of MCF7 cells 48 hours following treatment. Concentrations listed with
ES, MEF, DOX+ES, and DOX+MEF conditions refer to concentration of exosomes. All
treatments involving DOX used a concentration of 1 μM. Abbreviations: DOX: Doxorubicin;
ES: Embryonic stem cell; MEF: Mouse embryonic fibroblasts.
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Figure 6b. MTS assay of MDA-MB-231 cells 48 hours following treatment. Concentrations
listed with ES, MEF, DOX+ES, and DOX+MEF conditions refer to concentration of exosomes.
All treatments involving DOX used a concentration of 1 μM. Abbreviations: DOX: Doxorubicin;
ES: Embryonic stem cell; MEF: Mouse embryonic fibroblasts.
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Figure 6c. MTS assay of MDA-MB-468 cells 48 hours following treatment. N=14 for control,
DOX conditions; n=16 for ES, MEF, DOX+ES, and DOX+MEF conditions.
Note: Measurements are normalized to mean control values. Abbreviations: DOX: Doxorubicin;
ES: Embryonic stem cell; MEF: Mouse embryonic fibroblasts
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7.4. Real Time PCR Data
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Figure 7a. Real time PCR measurements of
miR-200c expression by MCF7 cells 48
hours following treatment with DOX, ES,
MEF, DOX+ES, and DOX+MEF.
Figure 7b. Real time PCR measurements of
miR-200c expression by MDA-MB-231
cells 48 hours following treatment.
Figure 7c. Real time PCR measurements of
miR-200c expression by MDA-MB-468
cells 48 hours following treatment.
Note: Columns represent fold change
compared to control using the 2‑ΔΔCT method
and normalized to snoRNA‑202.
Abbreviations: DOX: Doxorubicin; ES:
Embryonic stem cell; MEF: Mouse
embryonic fibroblasts.
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7.5. Western Blot Data
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Figure 8a. Expression of Bax by MCF7
cells 48 hours following treatment with
DOX, ES, DOX+ES, and DOX+MEF (n=2).
Figure 8b. Expression of Bcl-2 by MCF7
cells 48 hours following treatment (n=2).
Figure 8c. Ratio of Bax to Bcl-2 expression
by MCF7 cells (n=2).
Figure 8d. Representative Western blot
exposures showing expression of Bax and
Bcl-2 in MCF7 cells.
Note: GAPDH was used as a house-keeping
protein for loading control. Values are
relative to the mean of control values,
normalized to GAPDH. Abbreviations:
DOX: Doxorubicin; ES: Embryonic stem
cell; MEF: Mouse embryonic fibroblasts.
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Figure 9a. Expression of Bax by MDAMB-231 cells 48 hours following treatment
with DOX, ES, MEF, DOX+ES, and
DOX+MEF (n=2).
Figure 9b. Expression of Bcl-2 by MDAMB-231 cells 48 hours following treatment
(n=2).
Figure 9c. Ratio of Bax to Bcl-2 expression
by MDA-MB-231 cells (n=2).
Figure 9d. Representative Western blot
exposures showing expression of Bax and
Bcl-2 in MCF7 cells.
Note: GAPDH was used as a house-keeping
protein for loading control. Values are
relative to the mean of control values,
normalized to GAPDH. Abbreviations:
DOX: Doxorubicin; ES: Embryonic stem
cell; MEF: Mouse embryonic fibroblasts.
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Figure 10a. Expression of Bax by MDAMB-468 cells 48 hours following treatment
with DOX, ES, DOX+ES, and DOX+MEF
(n=2).
Figure 10b. Expression of Bcl-2 by MDAMB-468 cells 48 hours following treatment
(n=2).
Figure 10c. Ratio of Bax to Bcl-2
expression by MDA-MB-468 cells (n=2).
Figure 10d. Representative Western blot
exposures showing expression of Bax and
Bcl-2 in MCF7 cells.
Note: GAPDH was used as a house-keeping
protein for loading control. Values are
relative to the mean of control values,
normalized to GAPDH. Abbreviations:
DOX: Doxorubicin; ES: Embryonic stem
cell; MEF: Mouse embryonic fibroblasts.
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7.6. Cell Micrographs (Transmission Light Microscopy)
Control
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MEF

DOX

DOX+ES

DOX+MEF

Figure 11. Representative transmission light micrographs of MCF7 cells plated in wells of a 96well plate. Micrographs were taken 48 hours following treatment with DOX, ES, MEF,
DOX+ES and DOX+MEF. Note that the cells are firmly attached in the Control, ES and MEF
groups with fewer floating (dead) cells. Treatments with DOX show a large number of floating
rounded dead cells which were significantly less in the DOX+ES group compared to DOX alone
or DOX+MEF groups. Abbreviations: DOX: Doxorubicin; ES: Embryonic stem cell; MEF:
Mouse embryonic fibroblasts.
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Figure 12. Transmission light micrographs of MDA-MB-231 cells plated in wells of a 96-well
plate. Micrographs were taken 48 hours following treatment with DOX, ES, MEF, DOX+ES,
and DOX+MEF. Note that the cells are firmly attached in the Control, ES and MEF groups with
fewer floating (dead) cells. Treatments with DOX show a large number of floating, rounded
dead cells (and fewer viable cells) which were significantly less in the DOX+ES group compared
to DOX alone or DOX+MEF groups. Abbreviations: DOX: Doxorubicin; ES: Embryonic stem
cell; MEF: Mouse embryonic fibroblasts.
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Figure 13. Transmission light micrographs of MDA-MB-468 cells plated in wells of a 96-well
plate. Micrographs were taken 48 hours following treatment with DOX, ES, MEF, DOX+ES,
and DOX+MEF. Note that the cells are firmly attached in the Control, ES and MEF groups with
fewer floating (dead) cells. Treatments with DOX show a large number of floating, rounded
dead cells (and fewer viable cells) which were significantly less in the DOX+ES group compared
to DOX alone or DOX+MEF groups. Abbreviations: DOX: Doxorubicin; ES: Embryonic stem
cell; MEF: Mouse embryonic fibroblast.

